A dual C-C Motif Chemokine Receptor 2 (CCR2)/CCR5 antagonist, cenicriviroc (CVC), demonstrated improvement in NASH-related liver fibrosis and inhibition of steatohepatitis progression in a completed phase II clinical trial enrolling 289 patients with NASH (34). Here, CCR2 is linked to metabolic dysfunction-associated steatohepatitis.